Skip to main content
SpringerLink
Log in

Adjuvant Chemotherapy and Hormonal Therapy

  • Chapter
  • First Online:
Juvenile Angiofibroma

  • 543 Accesses

Abstract

The near exclusivity of juvenile angiofibroma to adolescent and young adult males points to an obvious hormonal influence. Immunohistochemical evaluations on tumor specimens have demonstrated receptors to testosterone and other sex hormones. Treatment with the anti-testosterone agent flutamide is currently the most accepted and efficacious modality to bring about presurgical tumor reduction. Six-week treatment with oral flutamide has been documented to be effective in bringing about tumor volume shrinkage in the postpubertal population (mean 16 %, maximum 40 %), but is expectedly ineffective in the prepubertal population who have negligible circulating testosterone levels. Presurgical tumor volume reduction has the potential to enable tumor excision by a less invasive approach, to facilitate tumor dissection from vital nerves and vessels, and to limit surgical complications and blood loss.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Johnson S, Kloster J, Schiff M. The action of hormones on juvenile nasopharyngeal angiofibroma. A case report. Acta Otolaryngol (Stockh). 1966;61:153–60.

    Article  Google Scholar 

  2. Martin H, Ehrlich H, Ables J. Juvenile nasopharyngeal angiofibroma. Ann Surg. 1948;127:513–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schiff M. Juvenile nasopharyngeal angiofibroma- a theory of pathogenesis. Laryngoscope. 1959;69:981–1016.

    Article  CAS  PubMed  Google Scholar 

  4. Brentani MM, Butugan O, Oshima CT, et al. Multiple steroid receptors in nasopharyngeal angiofibromas. Laryngoscope. 1989;99:398–401.

    Article  CAS  PubMed  Google Scholar 

  5. Hwang HC, Mills SE, Patterson K, Sown AM. Expression of androgen receptors in nasopharyngeal angiofibroma; an immunohistochemical study of 24 cases. Mod Pathol. 1998;11:1122–6.

    CAS  PubMed  Google Scholar 

  6. Farag MM, Ghanimah SE, Ragaie A, Saleem TH. Hormonal receptors in juvenile nasopharyngeal angiofibroma. Laryngoscope. 1987;97:208–11.

    Article  CAS  PubMed  Google Scholar 

  7. Hagen R, Romalo G, Sehwab B, Hoppe F, Schweikert H. Juvenile nasopharyngeal fibroma: androgen receptors and their significance for tumor growth. Laryngoscope. 1994;104:1125–9.

    Article  CAS  PubMed  Google Scholar 

  8. Gatalica Z. Immunohistochemical analysis of steroid hormone receptors in nasopharyngeal angiofibromas. Cancer Lett. 1998;127:89–93.

    Article  CAS  PubMed  Google Scholar 

  9. Montag AG, Tretiakova M, Richardson M. Steroid hormone receptor expression in nasopharyngeal angiofibromas. Consistent expression of estrogen receptor beta. Am J Clin Pathol. 2006;125:832–7.

    Google Scholar 

  10. Schick B, Dlugaiczyk J, Wendler O. Expression of sex hormone receptors in juvenile angiofibromas and antiproliferative effects of receptor modulators. Head Neck. 2014;36:1596–603.

    Article  PubMed  Google Scholar 

  11. Valanzano R, Curia MC, Aceto G, et al. Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumor. Gut. 2005;54:1046–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Thakar A, Gupta G, Bhalla AS, Jain V, Sharma SC, Sharma R, Bahadur S, Deka RC. Adjuvant therapy with flutamide for presurgical volume reduction in juvenile nasopharyngeal angiofibroma. Head Neck. 2011;33:1747–53.

    Article  PubMed  Google Scholar 

  13. Gates GA, Rice DH, Koopmann CF, Schuller DE. Flutamide-induced regression of angiofibroma. Laryngoscope. 1992;102:641–4.

    Article  CAS  PubMed  Google Scholar 

  14. Chabner BA, Ryan DP, Paz-Ares L, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill publishers; 2001. p. 1389–459.

    Google Scholar 

  15. Kerrigan JR, Veldhuis JD, Rogol AD. Androgen-receptor blockade enhances pulsatile luteinizing hormone production in late pubertal males: evidence for a hypothalamic site of physiologic androgen feedback action. Pediatr Res. 1994;35:102–6.

    Article  CAS  PubMed  Google Scholar 

  16. Muderris BF, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril. 2000;73:984–7.

    Article  CAS  PubMed  Google Scholar 

  17. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003;206:57–67.

    Article  PubMed  Google Scholar 

  18. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler Jr GB. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2000;85:1114–20.

    Article  CAS  PubMed  Google Scholar 

  19. Chu E, Sartorelli AC. Cancer chemotherapy. In: Katzung BG, editor. Basic and clinical pharmacology. 10th ed. New York: McGraw- Hill publishers; 2006. p. 878–907.

    Google Scholar 

  20. Labra A, Chavolla-Magaña R, Lopez-Ugalde A, Alanis-Calderon J, Huerta-Delgado A. Flutamide as a preoperative treatment in juvenile angiofibroma with intracranial invasion. Otolaryngol Head Neck Surg. 2004;130:466–9.

    Article  PubMed  Google Scholar 

  21. Howard DJ, Lloyd G, Lund V. Recurrence and its avoidance in juvenile angiofibroma. Laryngoscope. 2001;111:1509–11.

    Article  CAS  PubMed  Google Scholar 

  22. Thakar A, Hota A, Bhalla AS, Gupta SD, Sarkar C, Kumar R. Overt and occult Vidian canal involvement in juvenile angiofibroma and its possible impact on recurrence. Head Neck. 2016;38:E421–5.

    Article  PubMed  Google Scholar 

  23. Marshall AH, Bradley PJ. Management dilemmas in the treatment and follow-up of advanced JNA (review). ORL. 2006;68:273–8.

    Article  PubMed  Google Scholar 

  24. Spielmann PM, Adamson R, Cheng K, Sanderson RJ. Juvenile nasopharyngeal angiofibroma: spontaneous resolution. Ear Nose Throat J. 2008;87:521–3.

    Google Scholar 

  25. Weprin LS, Siemers PT. Spontaneous regression of juvenile nasopharyngeal angiofibroma. Arch Otolaryngol Head Neck Surg. 1991;117:796–9.

    Google Scholar 

  26. Dohar JE, Duvall AJ. Spontaneous regression of juvenile nasopharyngeal angiofibroma. Ann Otol Rhinol Laryngol. 1992;101:469–71.

    Article  CAS  PubMed  Google Scholar 

  27. Gullane PJ, Dacidson J, O’Dwyer T, Forte V. Juvenile angiofibroma: a review of the literature and a case series report. Laryngoscope. 1992;102:928–33.

    Article  CAS  PubMed  Google Scholar 

  28. Goepfert H, Cangir A, Lee YY. Chemotherapy for aggressive juvenile nasopharyngeal angiofibroma. Arch Otolaryngol. 1985;111:285–9.

    Article  CAS  PubMed  Google Scholar 

  29. Schick B, Kahle G, Hassler R, et al. Chemotherapy of juvenile angiofibroma—an alternative? HNO. 1996;44:148–52.

    CAS  PubMed  Google Scholar 

  30. Daniel W, Scholfield DW, Brundler M, McDermott A, Mussai F, Kearns P. Adjunctive treatment in juvenile nasopharyngeal angiofibroma: how should we approach recurrence? J Pediatr Hematol Oncol. 2016;38:235–9.

    Article  Google Scholar 

  31. Saylam G, Yu¨cel OT, Sungur A, et al. Proliferation, angiogenesis and hormonal markers in juvenile nasopharyngeal angiofibroma. Int J Pediatr Otorhinolaryngol. 2006;70:227–34.

    Article  PubMed  Google Scholar 

  32. Hota A, Sarkar C, Gupta SD, Kumar R, Bhalla AS, Thakar A. Expression of vascular endothelial growth factor in juvenile angiofibroma. Int J Pediatr Otorhinolaryngol. 2015;79:900–2.

    Article  PubMed  Google Scholar 

  33. Wendler O, Dlugaiczyk J, Birk S, et al. Anti-proliferative effect of glucocorticoids on mesenchymal cells in juvenile angiofibromas. Head Neck. 2012;34:1615–21.

    Article  PubMed  Google Scholar 

  34. Margolin JF, Soni HM, Pimpalwar S. Medical therapy for pediatric vascular anomalies. Semin Plast Surg. 2014;28:79–86.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology and Head-Neck Surgery, All India Institute of Medical Sciences, New Delhi, 110029, India

    Alok Thakar MS, FRCSEd

Authors
  1. Alok Thakar MS, FRCSEd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alok Thakar MS, FRCSEd .

Editor information

Editors and Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, Port Moresby General Hospital and School of Medicine and Health Sciences, University of Papua New Guinea, Boroko Port Moresby, Papua New Guinea

    Siba P. Dubey

  2. Department of Otolaryngology-Head and Neck Surgery, University of Saarlands Medical Center, Homburg/Saar, Saarland, Germany

    Bernhard Schick

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Thakar, A. (2017). Adjuvant Chemotherapy and Hormonal Therapy. In: Dubey, S., Schick, B. (eds) Juvenile Angiofibroma. Springer, Cham. https://doi.org/10.1007/978-3-319-45343-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45343-9_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45341-5

  • Online ISBN: 978-3-319-45343-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation